|Articles|November 1, 2017
- Pharmaceutical Executive-11-01-2017
- Volume 37
- Issue 11
Pharmaceutical Executive, November 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive November 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
Pharm Exec's 2018 Pipeline Reportover 8 years ago
Taiwan’s Biotech Boomalmost 9 years ago
The Fine Line of Pharma & Patient Group Collaborationalmost 9 years ago
FDA Explores Flexible Drug Marketing Policiesalmost 9 years ago
No Overnight Successesalmost 9 years ago
Aligning Early Advice with Long-Term Planningalmost 9 years ago
Navigating the Untapped NASH Marketalmost 9 years ago
Interpreting UK’s Post-Brexit Life Sciences Strategyalmost 9 years ago
When HIPAA Doesn’t Applyalmost 9 years ago
Country Report: AustriaAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5